Glycopyrrolate bromide: Phase III started

Last October, Sumitomo’s Sunovion Pharmaceuticals Inc. subsidiary began the open-label, international Phase III GOLDEN-5 trial to compare 50 ug SUN-101 twice daily vs. 18 ug Spiriva HandiHaler tiotropium once daily for 48 weeks in about 1,050 patients ages >=40. SUN-101 is delivered using the eFlow Nebulizer System from Pari GmbH (Starnberg, Germany). ...